Collective cancer invasion forms an integrin-dependent radioresistant niche
Cancer fatalities result from metastatic dissemination and therapy resistance, both processes that depend on signals from the tumor microenvironment. To identify how invasion and resistance programs cooperate, we used intravital microscopy of orthotopic sarcoma and melanoma xenografts. We demonstrat...
Saved in:
Published in | The Journal of experimental medicine Vol. 217; no. 1 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Rockefeller University Press
06.01.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Cancer fatalities result from metastatic dissemination and therapy resistance, both processes that depend on signals from the tumor microenvironment. To identify how invasion and resistance programs cooperate, we used intravital microscopy of orthotopic sarcoma and melanoma xenografts. We demonstrate that these tumors invade collectively and that, specifically, cells within the invasion zone acquire increased resistance to radiotherapy, rapidly normalize DNA damage, and preferentially survive. Using a candidate-based approach to identify effectors of invasion-associated resistance, we targeted β1 and αVβ3/β5 integrins, essential extracellular matrix receptors in mesenchymal tumors, which mediate cancer progression and resistance. Combining radiotherapy with β1 or αV integrin monotargeting in invading tumors led to relapse and metastasis in 40-60% of the cohort, in line with recently failed clinical trials individually targeting integrins. However, when combined, anti-β1/αV integrin dual targeting achieved relapse-free radiosensitization and prevented metastatic escape. Collectively, invading cancer cells thus withstand radiotherapy and DNA damage by β1/αVβ3/β5 integrin cross-talk, but efficient radiosensitization can be achieved by multiple integrin targeting. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 A. Haeger’s present address is Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. S. Kissler’s present address is Joslin Diabetes Center, Harvard Medical School, Boston, MA. S. Alexander’s present address is Cell Biology & Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany. A. Haeger and S. Alexander contributed equally to this work. F.M.P. Kaiser’s present address is Department of Immunology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, Netherlands. M. Hirschberg’s present address is Carl Zeiss Microscopy, Jena, Germany. |
ISSN: | 0022-1007 1540-9538 1540-9538 |
DOI: | 10.1084/jem.20181184 |